Dry powder nebulizer maker Nob Hill Therapeutics has named former Oriel Therapeutics President and CEO Paul Atkins as Executive Chairman. Atkins headed DPI developer Oriel until the company was acquired by Sandoz in 2010 and subsequently served as VP, Operations at Sandoz until 2020.
According to the Nob Hill web site, its DryNeb “dry powder nebulizer is a patented technology that can deliver drugs to the lower respiratory tract with much higher efficiency than current state of the art dry powder inhalers.” The DryNeb technology is licensed from the University of New Mexico.
Nob Hill Therapeutics CEO Yun Li commented, “It is a key milestone for Nob Hill Therapeutics as a company to grow from a young innovative startup to a key player in the field of inhaled medicine and therapy. With Dr. Atkins’s incredible leadership experience Nob Hill Therapeutics will speed up the development of its first therapy and build a product pipeline that addresses huge unmet needs in targeted therapy for lung infections and other lung diseases.”
Atkins said, “I am delighted to join the Nob Hill Therapeutics team at this time. Through careful incubation and the use of SBIR and seed funding, the company has moved the technology to the point where a range of potential clinical/commercial opportunities can now be realized. We have a knowledgeable and experienced team, and we are looking forward to move the DryNeb technology into clinical development.”
Read the Nob Hill Therapeutics press release.
